EcoDrugPlus

Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha)

Ensembl ID : ENSEEEG00000010151
Gene Symbol: PIK3R1
4 Cross references
253 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 3a (Gamma)

Ensembl ID : ENSEEEG00000002550
Gene Symbol: PIK3R3A
4 Cross references
199 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 3b (Gamma)

Ensembl ID : ENSEEEG00000008379
Gene Symbol: LOC113567981
4 Cross references
139 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSEEEG00000000635
Gene Symbol: PLA2G10
4 Cross references
232 Possible Orthologues:

Phospholipase A2, Group Vii (Platelet-Activating Factor Acetylhydrolase, Plasma)

Ensembl ID : ENSEEEG00000006576
Gene Symbol: PLA2G7
4 Cross references
206 Possible Orthologues:

Phospholipase A2-Like

Ensembl ID : ENSEEEG00000016570
Gene Symbol: LOC113585184
3 Cross references
175 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase

Ensembl ID : ENSEEEG00000018757
Gene Symbol: GART
2 Cross references
214 Possible Orthologues:

Plasminogen

Ensembl ID : ENSEEEG00000014538
Gene Symbol: PLG
4 Cross references
255 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSEEEG00000002691
Gene Symbol: PLAT
4 Cross references
207 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSEEEG00000006662
Gene Symbol: PTAFR
4 Cross references
224 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Alpha Polypeptide

Ensembl ID : ENSEEEG00000019575
Gene Symbol: PDGFRA
4 Cross references
204 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSEEEG00000014790
Gene Symbol: PDGFRB
4 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).